Denifanstat not checked
Ascletis · ASC40 · TVB-2640
FollowEvery change as it happens, and a Monday email
Trials
1 active
13 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Acne Vulgaris
- Main trialPhase 3
- “The purpose of this study is to evaluate the safety and efficacy of denifanstat compared with matching placebo in participants with moderate to severe acne vulgaris who are ≥12 years of age. After the 12-week treatment phase, a subset of approximately 530 participants will have the option to consent to an open-label extension phase for an additional 40 weeks of treatment.”In the company’s words, NCT07863193 on ClinicalTrials.gov
- Other names
- ASC40 · TVB-2640
Other drugs for Acne Vulgaris
- TrifaroteneGalderma R&D · Phase 3
- Cyproterone Acetate and Ethinyl EstradiolEurofarma Laboratorios S.A. · Phase 3
- ClascoteroneZhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Phase 3
- B244AOBiome LLC · Phase 2
- Acne mRNA vaccineSanofi · Phase 1/2
- HB0043Huahai Pharmaceutical (Huaota) · Phase 1/2
Coming up1
- Aug 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Aug 2027 | Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | |
| Phase 3Completed | 19 May 2025 | A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris | |
| Phase 3Unknown | Jun 2025 | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM | |
| Phase 3Completed | 12 Nov 2025 | A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris | |
| Phase 3Withdrawn | Jun 2026 | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH | |
| Phase 3Withdrawn | Dec 2030 | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis | |
| Phase 2Completed | 2 Oct 2021 | Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH) | |
| Phase 2Completed | 10 Apr 2023 | Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris | |
| Phase 2Completed | 2 Oct 2023 | Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) | |
| Phase 1Completed | 6 May 2021 | Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects | |
| Phase 1Completed | 21 Dec 2022 | Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects | |
| Phase 1Completed | 18 Dec 2023 | A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function | |
| Phase 1Completed | 20 Oct 2025 | A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026